Using oncolytic viruses to boost anti-tumor immunity
Official title: POTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATION
Funded at Icahn School of Medicine at Mount Sinai · NIH-11058395 · Data updated 2026-11-12
This study is looking at how a special virus can help your immune system fight advanced ovarian and colorectal cancers by boosting its ability to recognize and attack the cancer cells directly in the tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $611,086 |
| NIH project number | 5R01CA269382-04 |
| Project ID | NIH-11058395 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced ovarian or colorectal cancer who have not responded to standard treatments.
✕Less likely to help
Patients with early-stage cancer or those who have not been diagnosed with ovarian or colorectal cancer may not benefit from this research.
What this research studies
This research investigates the use of oncolytic viruses, specifically Newcastle Disease Virus, to enhance the immune response against tumors. By administering these viruses directly into tumors, the goal is to stimulate the body's immune system to recognize and attack cancer cells more effectively. The study also explores how these viruses interact with immune cells and the tumor microenvironment, aiming to improve treatment outcomes for patients with advanced ovarian and colorectal cancers.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that harness the body's own immune system to fight tumors.
How similar studies have gone: Previous studies have shown promise in using oncolytic viruses in cancer therapy, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Zamarin, Dmitriy — Icahn School of Medicine at Mount Sinai
- Study coordinator: Zamarin, Dmitriy
Related research
Other NIH-funded projects on the same topics.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Respiratory pathogen–specific T cell signatures after vaccination, infection, and treatment
A research effort to map how immune T cells respond to respiratory infections and vaccines, with potential to guide better vaccines and treatments for conditions like covid-19 and pertussis.
-
Malaria vaccine and infection: how the body’s early and later immune responses relate to protection
Researchers are studying how people’s immune systems respond to the malaria pre-erythrocytic stage, whether after vaccination or infection, to identify which responses are linked to protection.
-
Spatially responsive mass vaccination for urban rabies
A new plan uses data and maps to place vaccination sites where they’re most needed in cities, aiming to boost rabies vaccination for both people and dogs.
-
Spatially responsive mass vaccination for urban rabies
A project tests smarter placement of vaccination sites to increase mass canine rabies vaccination in cities.
-
Vaccine failure after Covid-19 vaccination in older adults
This project follows vaccinated older adults to understand who among them still gets Covid-19 and what factors make those outcomes worse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.